PV00091

Nom de l'organisation

i+Med S.Coop.

SRN

ES-MF-000008633

Statut du fabricant

Actif

9 avertissements enregistrés — faire défiler le panneau pour tout voir.

• CW009

  EUDAMED n'a pas publié de description pour ce code.
• CW001

  EUDAMED n'a pas publié de description pour ce code.
• CW135

  Keep out of children's reach. Jonexa Up should not be administered to children
• CW032

  The product should not be used after the expiration date
• CW276

  Do not use with other products containing quaternary ammonium salts as benzalkonium chloride or with any surgical material treated with this type of substances because sodium hyaluronate can precipitate in their presence. In order to prevent any possible interaction, avoid joint administration with other intra-articular products. There is no known interaction with other local anesthetics.
• CW161

  Jonexa Up should not be administeres to pregnant or breastfeeding women
• CW007

  The product should not be used if the package is damaged or broken
• CW999

  Do not administer Jonexa Up to patients with known hypersensitivity (allergy) to hyaluronic acid and / or other components of the product. Do not administer Jonexa Up to patients with acute or chronic dermatological disorders or an inflammatory and / or infectious type skin problem. Do not administer Jonexa Up to patients with coagulation defects and / or who are treated with anticoagulant medication.The use of Jonexa Up in any joint other than the knee and for other conditions has not been studied. Jonexa Up must be injected strictly into the intra-articular space following aseptic injection procedures. Jonexa Up should be administered with sterile Luer-lock needles. Do not inject into a blood vessel or surrounding tissues. To avoid pain after the injection, a recommendation should be given to keep the local site still after the injection. The syringe and the used needle should be discarded in a container provided for this purpose
• CW010

  EUDAMED n'a pas publié de description pour ce code.

Marché principal en Italie ; disponible dans 1 pays au total.

Dénomination commerciale

non renseigné

Code d'UDI-DI

08056515860761

Basic UDI-DI

B-08056515860761

Numéro de référence/catalogue

PV00091

Entité d'attribution

GS1

Catégorie de risque

Classe III

Législation applicable

MDD [Directive 93/42/CEE relative aux dispositifs médicaux]

Statut

Sur le marché

Quantité

1

Description complémentaire du produit

—

URL des informations complémentaires

Aucune URL d'informations complémentaires renseignée par le fabricant.

Dimensions cliniques

• 4.4 MU48

• P900402RESORBABLE FILLING AND RECONSTRUCTION DEVICES

• Numéro de lot
• Date d'expiration
• Date de fabrication
• Numéro de série
• Identification du logiciel

Santé des certificats sur le portefeuille de ce fabricant.